This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Oger, J. Articles by Gibbs, E. Search for Related Content PubMed Articles by Oger, J. Articles by Gibbs, E. Social Bookmarking                         What's this?

Binding antibodies: Vancouver's perspective

Department of Medicine, University of British Columbia, 2211 Wesbrook Mall, Vancouver, B.C. V6T 2B5, Canada, oger{at}interchange.ubc.ca

E. Gibbs

Department of Medicine, University of British Columbia, 2211 Wesbrook Mall, Vancouver, B.C. V6T 2B5, Canada

Binding antibodies (BAbs) and neutralizing antibodies (NAbs) develop following the use of interferon beta (IFNß) in patients with relapsing-remitting multiple sclerosis (RRMS). The appearance of anti-IFNß antibodies has been associated with reduction of the therapeutic efficacy of IFNß therapy; however, while BAbs and NAbs arise from exposure to IFNß, they have different characteristics and different impacts on clinical outcomes. Not all patients develop BAbs and NAbs, and patients who do may revert to seronegative status for each of these antibodies, even with continued IFNß treatment. This review examines the potential clinical and biological effect of BAbs and NAbs on therapeutic efficacy in the treatment of RRMS. Multiple Sclerosis 2007; 13: S36—S43. http://msj.sagepub.com

Key Words: Multiple sclerosis • antibodies • binding antibodies • neutralising antibodies • Interferons • anti-interferons

Multiple Sclerosis, Vol. 13, No. 1 suppl, 36-43 (2007)
DOI: 10.1177/1352458507076989


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?